Lundbeck increases research and development budget
Researchers and developers at Lundbeck will have more money to play with from 2020 onwards, as the company accelerates development on a number of drug candidates in order to ensure long-term growth.
Lundbeck's dream of building a larger and more attractive pipeline of new drug candidates means financial muscles will be flexed from 2020 onwards.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck has potential name for migraine drug: Vyepti
For abonnenter
